Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, first-in-human study of MET-409

Trial Profile

A Phase 1, first-in-human study of MET-409

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs MET-409 (Primary)
  • Indications Inflammatory bowel diseases; Irritable bowel syndrome; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 13 Jun 2018 According to a Metacrine media release, dosing of the first cohort has been completed in this trial.
    • 13 Jun 2018 According to a Metacrine media release, status changed from planning to recruiting.
    • 06 Jun 2018 According to a Metacrine media release, this trial is planned to begin later this month.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top